European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference